Insmed (INSM) Short-term Investments (2010 - 2026)
Insmed (INSM) posted quarterly Short-term Investments of $641.3 million for Q1 2026, down 19.45% year-over-year from $796.2 million in Q1 2025, and down 30.26% quarter-over-quarter from $919.6 million in Q4 2025.
Insmed (INSM) Short-term Investments (2010 - 2026) Analysis & Trends
Insmed's Short-term Investments history runs 9 years deep, the most recent figure standing at $641.3 million for Q1 2026.
- In Q1 2026, Short-term Investments fell 19.45% year-over-year to $641.3 million; the TTM figure through Mar 2026 stood at $641.3 million (down 19.45% YoY), while the FY2025 annual figure was $919.6 million, up 4.64% from the prior year.
- Short-term Investments for Q1 2026 stood at $641.3 million, down from $919.6 million in the prior quarter.
- The five-year high for Short-term Investments was $1.3 billion in Q3 2025, with the low at $29.8 million in Q1 2023.
- The 5-year median for Short-term Investments is $304.9 million (2023), against an average of $501.5 million.
- Peak annual rise in Short-term Investments reached 301.48% in 2023, while the deepest fall reached 75.07% in 2023.
- Insmed's Short-term Investments stood at $74.2 million in 2022, then soared by 301.48% to $298.1 million in 2023, then surged by 194.83% to $878.8 million in 2024, then grew by 4.64% to $919.6 million in 2025, then tumbled by 30.26% to $641.3 million in 2026.
- Business Quant data shows INSM's Short-term Investments at $641.3 million in Q1 2026, $919.6 million in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 615.55 Mn |
| Mar 31, 2026 | 641.33 Mn |
| Dec 31, 2025 | 919.60 Mn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 572.44 Mn |
| Mar 31, 2025 | 796.20 Mn |
| Dec 31, 2024 | 878.80 Mn |
| Sep 30, 2024 | 1.01 Bn |
| Dec 31, 2023 | 298.07 Mn |
| Sep 30, 2023 | 298.84 Mn |
| Jun 30, 2023 | 304.89 Mn |
| Mar 31, 2023 | 29.77 Mn |
| Dec 31, 2022 | 74.24 Mn |
| Sep 30, 2022 | 98.66 Mn |
| Jun 30, 2022 | 138.79 Mn |
| Mar 31, 2022 | 119.42 Mn |
| Jun 30, 2013 | 2.20 Mn |
| Mar 31, 2013 | 2.17 Mn |
| Dec 31, 2012 | 2.15 Mn |
| Sep 30, 2012 | 2.13 Mn |